|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
19 February 2015 |
|
Main ID: |
NCT01931488 |
|
Date of registration:
|
14/08/2013 |
|
Prospective Registration:
|
No |
|
Primary sponsor: |
|
|
Public title:
|
124I-MIBG Tracer Evaluation of Myocardial Sympathetic Denervation and Assessment of Neuroendocrine Tumors.
|
|
Scientific title:
|
The Feasibility of Novel 124I-MIBG Tracer in Evaluation of Myocardial Sympathetic Denervation and Assessment of Neuroendocrine Tumors. Comparison With 123I-MIBG. |
|
Date of first enrolment:
|
August 2013 |
|
Target sample size:
|
40 |
|
Recruitment status: |
Recruiting |
|
URL:
|
http://clinicaltrials.gov/show/NCT01931488 |
|
Study type:
|
Interventional |
|
Study design:
|
Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
|
|
Phase:
|
Phase 2
|
|
|
Countries of recruitment
|
|
Israel
| | | | | | | |
|
Contacts
|
|
Name:
|
ADVA RECHES |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
adva.reches@gmail.com |
|
Affiliation:
|
|
|
|
Name:
|
Einat Even Sapir, PhD, MD |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
Tel-Aviv Sourasky Medical Center |
| |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- Age = 18
- Signed Informed Consent
- Patients diagnosed with Parkinson disease
- Patients with histologically confirmed neuroendocrine tumors
Exclusion Criteria:
- Age < 18
- Any cardiovascular disease
- Taking medications that influence the sympathetic system
Age minimum:
18 Years
Age maximum:
N/A
Gender:
Both
|
|
Health Condition(s) or Problem(s) studied
|
|
Neuroendocrine Tumors
|
|
Parkinson Disease
|
|
Intervention(s)
|
|
Device: SPECT imaging
|
|
Other: MIBG label with I123 or I124
|
|
Primary Outcome(s)
|
|
Uptake of 123I-MIBG
[Time Frame: day 1]
|
|
Secondary ID(s)
|
|
TASMC-12-ES-0341-CTIL
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|